Novel antiplatelet activity of protocatechuic acid through the inhibition of high shear stress-induced platelet aggregation

Journal of Pharmacology and Experimental Therapeutics

Volumn 343, Issue 3, 2012, Pages 704-711

  Kim, Keunyoung ^a   Bae, Ok Nam ^c   Lim, Kyung Min ^a   Noh, Ji Yoon ^a   Kang, Seojin ^a   Chung, Ka Young ^b   Chung, Jin Ho ^a  

^a Seoul National University   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c Hanyang University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADHESION RECEPTOR; CALCIUM; CLOPIDOGREL; COLLAGEN; FERROUS CHLORIDE; FIBRINOGEN; GLYCOPROTEIN IB; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; PADGEM PROTEIN; PROTOCATECHUIC ACID; RECEPTOR; SEROTONIN; THROMBIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTITHROMBOTIC ACTIVITY; ARTERY THROMBOSIS; ARTICLE; BLEEDING TIME; CALCIUM MOBILIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; EX VIVO STUDY; FLOWER; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; LONICERA; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RAT; SEROTONIN RELEASE; SHEAR STRESS; SINGLE DRUG DOSE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION;

ADOLESCENT; ADULT; ANIMALS; BLOOD PLATELETS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOWERS; HEMORRHAGE; HUMANS; HYDROXYBENZOATES; LONICERA; MALE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; STRESS, MECHANICAL; THROMBOSIS; VON WILLEBRAND FACTOR; YOUNG ADULT;

EID: 84869204916     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.198242     Document Type: Article

References (58)

1. Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, et al. (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373:1849-1860.
2. Barrett NE, Holbrook L, Jones S, Kaiser WJ, Moraes LA, Rana R, Sage T, Stanley RG, Tucker KL, Wright B, et al. (2008) Future innovations in anti-platelet therapies. Br J Pharmacol 154:918-939. (Pubitemid 351915054)
3. Benard SA, Smith TM, Cunningham K, Jacob J, DeSilva T, Lin L, Shaw GD, Kriz R, and Kelleher KS (2008) Identification of peptide antagonists to glycoprotein Ibα that selectively inhibit von Willebrand factor dependent platelet aggregation. Biochemistry 47:4674-4682. (Pubitemid 351555488)
4. Cao YG, Zhang L, Ma C, Chang BB, Chen YC, Tang YQ, Liu XD, and Liu XQ (2009) Metabolism of protocatechuic acid influences fatty acid oxidation in rat heart: new anti-angina mechanism implication. Biochem Pharmacol 77:1096-1104.
5. Chang WC and Hsu FL (1992) Inhibition of platelet activation and endothelial cell injury by polyphenolic compounds isolated from Lonicera japonica Thunb. Prostaglandins Leukot Essent Fatty Acids 45:307-312.
6. Chen L, Bracey AW, Radovancevic R, Cooper JR Jr, Collard CD, Vaughn WK, and Nussmeier NA (2004) Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting. J Thorac Cardiovasc Surg 128:425-431. (Pubitemid 39194700)
7. Cifuni SM, Wagner DD, and Bergmeier W (2008) CalDAG-GEFI and protein kinase C represent alternative pathways leading to activation of integrin αIIbß3 in platelets. Blood 112:1696-1703.
8. Clemetson KJ and Clemetson JM (2008) Platelet GPIb complex as a target for anti-thrombotic drug development. Thromb Haemost 99:473-479. (Pubitemid 351549283)
9. 14C]protocatechuic acid in the rat. Aromatic dehydroxylation. J Pharm Pharmacol 20:610-618.
10. Davì G and Patrono C (2007) Platelet activation and atherothrombosis. N Engl J Med 357:2482-2494.
11. Dong JF, Berndt MC, Schade A, McIntire LV, Andrews RK, and López JA (2001) Ristocetin-dependent, but not botrocetin-dependent, binding of von Willebrand factor to the platelet glycoprotein Ib-IX-V complex correlates with shear-dependent interactions. Blood 97:162-168. (Pubitemid 32061256)
12. Firbas C, Siller-Matula JM, and Jilma B (2010) Targeting von Willebrand factor and platelet glycoprotein Ib receptor. Expert Rev Cardiovasc Ther 8:1689-1701.
13. Gilbert JC, DeFeo-Fraulini T, Hutabarat RM, Horvath CJ, Merlino PG, Marsh HN, Healy JM, Boufakhreddine S, Holohan TV, and Schaub RG (2007) First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation 116:2678-2686. (Pubitemid 350291240)
14. Goto S, Ikeda Y, Saldivár E, and Ruggeri ZM (1998) Distinct mechanisms of platelet aggregation as a consequence of different shearing flow conditions. J Clin Invest 101:479-486. (Pubitemid 28067346)
15. 12) in platelet activation initiated by binding of von Willebrand factor to platelet GP Ibα induced by conditions of high shear rate. Circulation 105:2531-2536.
16. Han Y, Xiong Z, Yang C, Liu M, and Li F (2007) [Determination of protocatechuic acid in rat plasma by high performance liquid chromatography.] Se Pu 25:207-210.
17. Huizinga EG, Tsuji S, Romijn RA, Schiphorst ME, de Groot PG, Sixma JJ, and Gros P (2002) Structures of glycoprotein Ibα and its complex with von Willebrand factor A1 domain. Science 297:1176-1179. (Pubitemid 36196734)
18. Jackson SP and Schoenwaelder SM (2003) Antiplatelet therapy: in search of the 'magic bullet'. Nat Rev Drug Discov 2:775-789. (Pubitemid 37361810)
19. Jurk K and Kehrel BE (2005) Platelets: physiology and biochemistry. Semin Thromb Hemost 31:381-392. (Pubitemid 41362342)
20. Kiefer TL and Becker RC (2009) Inhibitors of platelet adhesion. Circulation 120:2488-2495.
21. Kroll MH and Feng S (2005) Targeting shear stress-induced platelet activation: is lesion-specific antiplatelet therapy a realistic clinical goal? Expert Rev Cardiovasc Ther 3:941-951. (Pubitemid 41448207)
22. Kroll MH, Hellums JD, McIntire LV, Schafer AI, and Moake JL (1996) Platelets and shear stress. Blood 88:1525-1541. (Pubitemid 26307046)
23. Kulkarni S, Dopheide SM, Yap CL, Ravanat C, Freund M, Mangin P, Heel KA, Street A, Harper IS, Lanza F, et al. (2000) A revised model of platelet aggregation. J Clin Invest 105:783-791. (Pubitemid 30164117)
24. Kurlbaum M and Högger P (2011) Plasma protein binding of polyphenols from maritime pine bark extract (USP). J Pharm Biomed Anal 54:127-132.
25. Lee EJ, Kim JS, Kim HP, Lee JH, and Kang SS (2010) Phenolic constituents from the flower buds of Lonicera japonica and their 5-lipoxygenase inhibitory activities. Food Chem 120:134-139.
26. Lee MJ, Chou FP, Tseng TH, Hsieh MH, Lin MC, and Wang CJ (2002) Hibiscus protocatechuic acid or esculetin can inhibit oxidative LDL induced by either copper ion or nitric oxide donor. J Agric Food Chem 50:2130-2136.
27. Lefkovits J, Plow EF, and Topol EJ (1995) Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 332:1553-1559.
28. Lenting PJ, Pegon JN, Groot E, and de Groot PG (2010) Regulation of von Willebrand factor-platelet interactions. Thromb Haemost 104:449-455.
29. Lin HH, Chen JH, Chou FP, and Wang CJ (2011) Protocatechuic acid inhibits cancer cell metastasis involving the down-regulation of Ras/Akt/NF-κB pathway and MMP-2 production by targeting RhoB activation. Br J Pharmacol 162:237-254.
30. Masella R, Santangelo C, D'Archivio M, LiVolti G, Giovannini C, and Galvano F (2012) Protocatechuic acid and human disease prevention: biological activities and molecular mechanisms. Curr Med Chem 19:2901-2917.
31. Maxwell MJ, Westein E, Nesbitt WS, Giuliano S, Dopheide SM, and Jackson SP (2007) Identification of a 2-stage platelet aggregation process mediating shear-dependent thrombus formation. Blood 109:566-576. (Pubitemid 46105955)
32. Mazzucato M, Cozzi MR, Pradella P, Ruggeri ZM, and De Marco L (2004) Distinct roles of ADP receptors in von Willebrand factor-mediated platelet signaling and activation under high flow. Blood 104:3221-3227. (Pubitemid 39507138)
33. Mazzucato M, Pradella P, Cozzi MR, De Marco L, and Ruggeri ZM (2002) Sequential cytoplasmic calcium signals in a 2-stage platelet activation process induced by the glycoprotein Ibalpha mechanoreceptor. Blood 100:2793-2800.
34. Michelson AD (2010) Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov 9:154-169.
35. Mistry N, Cranmer SL, Yuan Y, Mangin P, Dopheide SM, Harper I, Giuliano S, Dunstan DE, Lanza F, Salem HH, et al. (2000) Cytoskeletal regulation of the platelet glycoprotein Ib/V/IX-von Willebrand factor interaction. Blood 96:3480-3489.
36. Miyata S, Goto S, Federici AB, Ware J, and Ruggeri ZM (1996) Conformational changes in the A1 domain of von Willebrand factor modulating the interaction with platelet glycoprotein Ibα. J Biol Chem 271:9046-9053. (Pubitemid 26123336)
37. Miyazaki Y, Nomura S, Miyake T, Kagawa H, Kitada C, Taniguchi H, Komiyama Y, Fujimura Y, Ikeda Y, and Fukuhara S (1996) High shear stress can initiate both platelet aggregation and shedding of procoagulant containing microparticles. Blood 88:3456-3464. (Pubitemid 26365580)
38. Nesbitt WS, Kulkarni S, Giuliano S, Goncalves I, Dopheide SM, Yap CL, Harper IS, Salem HH, and Jackson SP (2002) Distinct glycoprotein Ib/V/IX and integrin αIIbß3-dependent calcium signals cooperatively regulate platelet adhesion under flow. J Biol Chem 277:2965-2972. (Pubitemid 34953332)
39. Nesbitt WS, Westein E, Tovar-Lopez FJ, Tolouei E, Mitchell A, Fu J, Carberry J, Fouras A, and Jackson SP (2009) A shear gradient-dependent platelet aggregation mechanism drives thrombus formation. Nat Med 15:665-673.
40. Philipose S, Konya V, Sreckovic I, Marsche G, Lippe IT, Peskar BA, Heinemann A, and Schuligoi R (2010) The prostaglandin E2 receptor EP4 is expressed by human platelets and potently inhibits platelet aggregation and thrombus formation. Arterioscler Thromb Vasc Biol 30:2416-2423.
41. Quinton TM, Kim S, Dangelmaier C, Dorsam RT, Jin J, Daniel JL, and Kunapuli SP (2002) Protein kinase C- and calcium-regulated pathways independently synergize with Gi pathways in agonist-induced fibrinogen receptor activation. Biochem J 368:535-543. (Pubitemid 35454531)
42. Radtke J, Linseisen J, and Wolfram G (1998) Phenolic acid intake of adults in a Bavarian subgroup of the national food consumption survey. Z Ernahrungswiss 37:190-197. (Pubitemid 28318362)
43. Ruggeri ZM, Dent JA, and Saldivár E (1999) Contribution of distinct adhesive interactions to platelet aggregation in flowing blood. Blood 94:172-178. (Pubitemid 29300146)
44. Sadler JE (2002) Biomedicine. Contact - how platelets touch von Willebrand factor. Science 297:1128-1129.
45. Scarborough RM, Kleiman NS, and Phillips DR (1999) Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use? Circulation 100:437-444. (Pubitemid 29362416)
46. Serebruany VL, Malinin AI, Eisert RM, and Sane DC (2004) Risk of bleeding complications with antiplatelet agents: meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials. Am J Hematol 75:40-47. (Pubitemid 38040166)
47. Sostres C and Lanas A (2011) Gastrointestinal effects of aspirin. Nat Rev Gastroenterol Hepatol 8:385-394.
48. Speich HE, Grgurevich S, Kueter TJ, Earhart AD, Slack SM, and Jennings LK (2008) Platelets undergo phosphorylation of Syk at Y525/526 and Y352 in response to pathophysiological shear stress. Am J Physiol Cell Physiol 295:C1045-C1054.
49. Tomás-Barberán FA and Clifford MN (2000) Dietary hydroxybenzoic acid derivatives - nature, occurrence and dietary burden. J Sci Food Agric 80:1024-1032. (Pubitemid 30319396)
50. Tsuji S, Sugimoto M, Miyata S, Kuwahara M, Kinoshita S, and Yoshioka A (1999) Real-time analysis of mural thrombus formation in various platelet aggregation disorders: distinct shear-dependent roles of platelet receptors and adhesive proteins under flow. Blood 94:968-975. (Pubitemid 29361828)
51. Varga-Szabo D, Pleines I, and Nieswandt B (2008) Cell adhesion mechanisms in platelets. Arterioscler Thromb Vasc Biol 28:403-412.
52. Vitaglione P, Donnarumma G, Napolitano A, Galvano F, Gallo A, Scalfi L, and Fogliano V (2007) Protocatechuic acid is the major human metabolite of cyanidin-glucosides. J Nutr 137:2043-2048. (Pubitemid 47367263)
53. Wadanoli M, Sako D, Shaw GD, Schaub RG, Wang Q, Tchernychev B, Xu J, Porter TJ, and Huang Q (2007) The von Willebrand factor antagonist (GPG-290) prevents coronary thrombosis without prolongation of bleeding time. Thromb Haemost 98:397-405. (Pubitemid 47260291)
54. Wang X, Dorsam RT, Lauver A, Wang H, Barbera FA, Gibbs S, Varon D, Savion N, Friedman SM, and Feuerstein GZ (2002) Comparative analysis of various platelet glycoprotein IIb/IIIa antagonists on shear-induced platelet activation and adhesion. J Pharmacol Exp Ther 303:1114-1120. (Pubitemid 35424396)
55. Yende S and Wunderink RG (2001) Effect of clopidogrel on bleeding after coronary artery bypass surgery. Crit Care Med 29:2271-2275. (Pubitemid 34038157)
56. Yin MC, Lin CC, Wu HC, Tsao SM, and Hsu CK (2009) Apoptotic effects of protocatechuic acid in human breast, lung, liver, cervix, and prostate cancer cells: potential mechanisms of action. J Agric Food Chem 57:6468-6473.
57. Yun-Choi HS, Kim JH, and Lee JR (1987) Potential inhibitors of platelet aggregation from plant sources, III. J Nat Prod 50:1059-1064. (Pubitemid 18030553)
58. Zhang YJ, Wu L, Zhang QL, Li J, Yin FX, and Yuan Y (2011) Pharmacokinetics of phenolic compounds of Danshen extract in rat blood and brain by microdialysis sampling. J Ethnopharmacol 136:129-136.